According to Benzinga Pro data, during Q2, Nurix Therapeutics (NASDAQ:NRIX) posted sales of $30.68 million. Earnings were up 40.4%, but Nurix Therapeutics still reported an overall loss of $24.28 million. Nurix Therapeutics collected $12.69 million in revenue during Q1, but reported earnings showed a $40.73 million loss.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Nurix Therapeutics posted an ROCE of -0.09%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Nurix Therapeutics, a negative ROCE ratio of -0.09% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Upcoming Earnings Estimate

Nurix Therapeutics reported Q2 earnings per share at $-0.45/share, which beat analyst predictions of $-0.56/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.